Paraquat Settlement Quiz
If you or someone you know was diagnosed with Parkinson’s Disease after exposure to Paraquat, you may be eligible for a significant settlement.
100% Privacy
Guaranteed
3 EASY STEPS
QUICK QUIZ,
QUICK ANSWERS!
Start by answering a few questions and quickly discover your eligibility. If you qualify, we’re one step closer to helping you.
SIGN ONLINE WITH NO OBLIGATIONS
If eligible, you’ll then receive your DocuSign (retainer) to help us help you. Think of it as a car key for your case. Without it, we can’t proceed. Signing isn’t a commitment, and you can opt out anytime.
PROGRESSING TOWARDS COMPENSATION
If you qualify, expect a team member to call within 24 hours. All information remains 100% confidential, and all necessary steps can be completed online!
Paraquat Use in the United States
Our partner law firms have helped injured individuals across all 50 states recover $3 billion.
100+
Trusted partners
100%
Free and Confidential
Case Review
Instant
Case Results Available 24/7
3x more likely to win your Paraquat case and secure a 2x larger settlement with the right lawyer.
Frequently Asked Questions
Introduction to Paraquat: Understanding Its Role and Risks
Paraquat, known scientifically as methyl viologen or N, N′-dimethyl-4,4′-bipyridinium dichloride, stands as a potent herbicide for managing weeds and grass across various agricultural settings. Its effectiveness spans from fruit orchards to crop rows, offering broad-spectrum control. However, its use comes with significant safety measures in the U.S., including coloration for easy identification, an odor warning, and an emetic agent to prevent ingestion, given its high toxicity.
A Glimpse into Paraquat’s Development and Usage
Discovered in the late 19th century, Paraquat’s herbicidal qualities were highlighted in the 1950s, leading to its commercialization as Gramoxone by Imperial Chemical Industries in 1962. While Gramoxone is a well-known brand, Paraquat is also found in products like Parazone and Cyclone, among others, with Syngenta being a leading manufacturer today.
Safety Measures and Controversies
Despite safety enhancements, Paraquat’s toxic nature has led to severe health risks upon exposure. Its link to conditions like Parkinson’s disease has prompted over 50 countries to ban its use. Yet, the U.S. continues its regulated application, even as legal actions unfold against manufacturers for failing to warn of the risks effectively.
Legal Battles and Ongoing Litigation
The legal landscape has seen numerous lawsuits alleging Paraquat’s connection to Parkinson’s disease and other health issues. These cases have coalesced into a Multi-District Litigation (MDL) in Illinois, aiming to address the grievances of those affected. The outcomes of these bellwether trials may set precedents for future settlements and further highlight the need for stringent safety protocols.
Navigating a Paraquat Lawsuit
For those impacted by Paraquat, pursuing legal action requires detailed documentation of exposure and medical history. Legal representation specializing in Paraquat cases can guide plaintiffs through the complexities of the litigation process, aiming to secure compensation for the damages endured.
The Path Forward
As legal proceedings continue, affected individuals and families look toward the outcomes for closure and justice. The situation underscores the importance of regulatory diligence and the ongoing debate over the safety of agricultural chemicals. Awareness and advocacy remain crucial in navigating the challenges posed by substances like Paraquat.
Stay Updated
For those seeking the latest developments in Paraquat litigation and safety information, staying informed through reputable sources is essential. As this situation evolves, the affected communities and legal teams work tirelessly to address the consequences of Paraquat exposure
The compensation potential available is based on a Parkinson’s Disease diagnosis. If you have any of the following symptoms, you may want to consult a doctor.
Parkinson’s Disease Symptoms:
- Tremors
- Shaking or trembling
- Small handwriting
- Prolonged or extreme stiffness
- Difficulty with body movements
- Loss of balance
- Difficulty walking (slow gait)
- Difficulty or soft speaking
- Reduced facial expression
- Drooling
- Whole body fatigue or dizziness
- Early Awakenings or sleep disturbances
- Hallucinations
- Delusions
- Amnesia or confusion in evening hours
- Anxiety
- Apathy
Parkinson’s Disease Medications:
- Amantadine
- Apokyn (apmorphie hydrocholride injection)
- Artane (trihexyphenidyl HCL)
- Axilect (rasagiline)
- Cogentin (benztropine)
- Elepryl (selegiline)
- KYNMOBI (Apomorphine hydrochloride)
- Levodopa (Sinemet, Stalevo, Larodopa)
- Mirapex (pramipexole)
- Neupro (Rotigotine Transdermal System)
- Nourizanz(istradefylline)
- Requip (ropinirole)
- Xadago (safinamide)
- Zelapar (Selegiline HCL orally disintegrating)
Paraquat Lawsuit Recent Updates
February 19th, 2024:
Chief U.S. District Judge Nancy Rosenstengel has recently appointed nine new plaintiffs, in the Paraquat Dichloride MDL, to replace those in previous claims that have been dismissed due to concerns over their validity. The litigation currently encompasses over 5,000 claims, consolidated from various federal jurisdictions. The herbicide is known for its negative neurological effects.
Judge Rosenstengel initially identified six plaintiffs for early trial phases, aiming to set precedent for subsequent cases. However, challenges such as unconvincing liability theories and evidentiary issues have led to the dismissal of several claims.
Judge Rosenstengel has set a crucial deadline for the completion of dispositions and third-party discovery processes, specfically focusing on distinguishing claims that lack a direct correlation to Paraquat exposure. Special Master Randi Ellis is tasked with overseeing document requests and third-party depositions.
This includes obtaining subpoenas for retail purchase records and affidavits from supervisors verifying the plaintiffs’ exposure to Paraquat. In taking a meticulous approach to ensure claim validity, the court has not yet finalized a trial schedule.
January 23, 2024:
The Court addressed concerns regarding implausible theories of liability in paraquat exposure cases through Case Management Order No. 18 (CMO 18). The order identified 25 cases with questionable claims and mandated limited discovery to assess their viability. This initiative aims to streamline the docket by addressing cases lacking substantial evidence.
January 4th, 2024:
The Paraquat MDL now encompasses over 5,000 pending cases. However, the past month has seen a notable decrease in case volume, with only 86 new cases added. This marks the lowest monthly case volume in more than two years, and it is the second consecutive month with unusually low activity.
The final week of 2023 proved to be a sluggish period for the Paraquat class action MDL docket. A total of twelve new cases were directly filed within the MDL, and an additional ten cases were transferred in from other districts.
November 1st, 2023:
Dr. Douglas Weed is seeking to quash a subpoena from the plaintiffs’ attorneys, which is related to his article on paraquat’s potential link to Parkinson’s disease. In his article, titled “Does paraquat cause Parkinson’s disease? A review of reviews,” published in the journal NeuroToxicology in September 2021, he concludes that there is a scientific consensus that paraquat does not cause Parkinson’s disease.
Dr. Weed argues that he has no direct involvement in the case and contends that the extensive document requests are overly burdensome, relate to ongoing research, and exceed the geographical limits defined by Rule 45.
The plaintiffs’ attorneys are interested in understanding how he reached this conclusion, particularly in regard to his funding disclosure, which lacks a specific grant for the article. They have until the end of this week to respond to the motion.